References

Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164

10.1200/jco.19.02107 · 2020 · External reference

Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study

10.1200/jco.19.02105 · 2020 · External reference

Pembrolizumab in microsatellite-instability–high advanced colorectal cancer

10.1056/nejmoa2017699 · 2020 · External reference

Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status

10.1001/jamaoncol.2018.4942 · 2019 · External reference

Classification and characterization of microsatellite instability across 18 cancer types

10.1038/nm.4191 · 2016 · External reference

Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1

10.1158/1078-0432.ccr-16-1741 · 2017 · External reference

Relationship between MLH1 promoter methylation, RAS/BRAF mutations, and response to immune checkpoint inhibitors in patients with advanced colorectal cancer

2020 · External reference

Analysis of somatic microsatellite indels identifies driver events in human tumors

10.1038/nbt.3966 · 2017 · External reference

Landscape of microsatellite instability across 39 cancer types

2017 · External reference

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

10.1016/j.ejca.2025.115338 · 2025 · External reference

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials

10.1016/s1470-2045(19)30691-6 · 2020 · External reference

Precision targeted therapy with BLU-667 for RET-driven cancers

10.1158/2159-8290.cd-18-0338 · 2018 · External reference

Prognostic impact of clinical factors in MSI-H/dMMR gastrointestinal tumors treated with immune checkpoint inhibitors: results from a multicenter real-world study

2026 · External reference

Unraveling resistance to immunotherapy in MSI-high colorectal cancer

10.3390/cancers15205090 · 2023 · External reference

Genetic mechanisms of mmune evasion in colorectal cancer

10.1158/2159-8290.cd-17-1327 · 2018 · External reference

Microsatellite instability and metastatic colorectal cancer: a clinical perspective

10.3389/fonc.2022.888181 · 2022 · External reference

Mechanisms and strategies to overcome drug resistance in colorectal cancer

10.3390/ijms26051988 · 2025 · External reference